12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Other News

Amarin cardiovascular news

Amarin said the U.S. Patent and Trademark Office (PTO) issued U.S. Patent Nos. 8,793,727 and 8,293,728 covering Vascepa icosapent ethyl (formerly AMR101) to treat hypertriglyceridemia -- its approved indication. The company said the PTO issued Notices of Allowance last month...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >